The 9 analysts offering 12-month price forecasts for Fulcrum Therapeutics Inc have a median target of 27.00, with a high estimate of 43.00 and a low estimate of 7.00. The median estimate represents a +446.56% increase from the last price of 4.94.
The current consensus among 9 polled investment analysts is to Buy stock in Fulcrum Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.66
Reporting Date Aug 29
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.